ライフサイエンスコーパス: intravenous

1 eive intravenous 1.26% sodium bicarbonate or intravenous 0.9% sodium chloride and 5 days of oral acet

2 and drug reactions were rare in both groups (intravenous: 0.7%, oral: 0.5%).

3 ho were scheduled for angiography to receive intravenous 1.26% sodium bicarbonate or intravenous 0.9%

4 Patients who needed intravenous acetylcysteine treatment for paracetamol ove

5 patients with SMA1 received a single dose of intravenous adeno-associated virus serotype 9 carrying S

6 Cangrelor is a potent intravenous adenosine diphosphate-receptor antagonist th

7 enetration of the brain parenchyma following intravenous administration in mice.

8 In the adult mouse, intravenous administration of 1 x 10(11) vector genomes

9 analyzed ex vivo at 3, 6, 24, and 96 h after intravenous administration of 25 mug of (89)Zr-MSB001085

10 ntervention (control, CONT) as well as after intravenous administration of either propranolol (PROP),

11 Intravenous administration of etelcalcetide (n = 503) or

12 If this hypothesis is valid, intravenous administration of MSCs should improve outcom

13 Intravenous administration of the MagMBs to mice bearing

14 In addition, the intravenous administration of tocotrienol entrapped in t

15 occur in the body as a result of therapeutic intravenous administration, surgery, infections or decom

16 th the observed plasma clearance values upon intravenous administration.

17 ility to specifically reach tumors following intravenous administration.

18 s models and aqueous solubility suitable for intravenous administration.

19 Both conditions were performed under intravenous alcohol administration (6% vol/vol infusion

20 participants could press a button to receive intravenous alcohol using the Computerized Alcohol Infus

21 domly assigned to medical therapy (including intravenous alteplase when eligible) and neurovascular t

22 her microscopy or culture, to receive either intravenous amphotericin B deoxycholate (amphotericin) (

23 nal responses during the first 4 hours after intravenous and intragastric Pi loading in rats.

24 expression of miR-194 enhanced metastasis of intravenous and intraprostatic tumor xenografts.

25 growth in vivo during treatment through both intravenous and non-local subcutaneous injections.

26 dicitis, although existing studies comparing intravenous and oral antibiotics for this purpose are li

27 el II and III evidence supporting the use of intravenous and oral antiviral therapy for the treatment

28 es were obtained by transducing a peripheral intravenous and pulmonary artery catheter, respectively,

29 The pharmacokinetics shows that both intravenous and subcutaneous applications are viable rou

30 rotocol, and avoiding the unnecessary use of intravenous and urinary tract catheters.

31 d, including intracoronary, intramyocardial, intravenous, and epicardial.

32 e per week or mFOLFOX (oxaliplatin, 85 mg/m2 intravenous, and fluorouracil, 2400 mg/m2 intravenous in

33 Intravenous anesthetic propofol binds to 5-lipoxygenase

34 be directly activated and potentiated by the intravenous anesthetic propofol.

35 Propofol is an intravenous anesthetic that produces its anesthetic effe

36 Notably, intensive intravenous antibiotic treatment of patients with melioi

37 Compared with oral antibiotics, use of intravenous antibiotics after discharge in children with

38 ed (median: 99/hospital), and utilization of intravenous antibiotics after discharge ranged from 0% t

39 icated appendicitis who received oral versus intravenous antibiotics after discharge.

40 ur case, early recognition, culture-specific intravenous antibiotics and urgent surgical treatment co

41 re is increasing interest in using high-dose intravenous ascorbate (IVC) in treating this disease par

42 n macrophages and boosted protection against intravenous bacterial challenge.

43 taxel (175 mg/m(2) on day 1) with or without intravenous bevacizumab (15 mg/kg on day 1) in 21 day cy

44 reatment as the control group plus 7.5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemo

45 cination approach, direct tumor injection or intravenous biodistribution to an orthotopic PDAC site.

46 alog whose potency and duration of action on intravenous bolus injection in diabetic rats are indisti

47 es; bortezomib (1.3 mg/m(2)) was given as an intravenous bolus or subcutaneous injection on days 1, 4

48 ndomly assigned (1:1) to ketamine (0.5 mg/kg intravenous bolus) or saline adjunctive to the anaesthet

49 ive voice and web response system to receive intravenous brentuximab vedotin 1.8 mg/kg once every 3 w

50 ely in four equal doses); after Nov 8, 2007, intravenous busulfan was given (0.8-1.2 mg/kg per dose f

51 Intravenous but not gastric Pi loading in parathyroidect

52 bitors, including prasugrel, ticagrelor, and intravenous cangrelor.

53 th other AMPs, in the treatment of S. aureus intravenous catheter infections.

54 multivariate regression analysis, only early intravenous catheter removal (on day 2) [odds ratio: 0.3

55 elow the knee, a single preoperative dose of intravenous cefazolin compared with saline did not reduc

56 ptibility, presence of fever, comorbidities (intravenous central lines, urinary catheters, diabetes m

57 ite of action is indicated by the ability of intravenous CGRP to trigger migraine in humans and the e

58 HI-EOL care comprised any of the following: intravenous chemotherapy < 14 days from death; more than

59 eview of Group D eyes treated initially with intravenous chemotherapy (IVC) and followed up for at le

60 Low-risk intravenous chemotherapy agents had overuse that continu

61 the outcomes of retinoblastoma treated with intravenous chemotherapy and IVM as salvage for vitreous

62 ous seeding from retinoblastoma treated with intravenous chemotherapy and IVM from 2012 to 2016.

63 1:1:1 (blocking used; block size of four) to intravenous chemotherapy of either cisplatin (50 mg/m(2)

64 ts, with highest rates among those receiving intravenous chemotherapy with high chemotherapy-induced

65 tomycin (one dose of 12 mg/m(2) on day 1) or intravenous cisplatin (one dose of 60 mg/m(2) on days 1

66 e-blind, counterbalanced design, CD received intravenous cocaine (30 mg/70 kg) before one session (CD

67 ked on developing a second-order schedule of intravenous cocaine reinforcement to investigate the neu

68 Intravenous colistin is difficult to use because plasma

69 on by computed tomography scan with oral and intravenous contrast is safe and feasible, whereas perfo

70 Purpose To assess the effect of intravenous contrast media on renal function in neonates

71 tion rate in the cohort that received 5-hour intravenous corticosteroid prophylaxis.

72 0-30) oral corticosteroids (PUCAI 35-60), or intravenous corticosteroids (PUCAI >/=65).

73 y week 12 in patients initially treated with intravenous corticosteroids included baseline total Mayo

74 nts, all of whom were initially treated with intravenous corticosteroids, underwent colectomy.

75 presenting with severe disease and requiring intravenous corticosteroids.

76 colectomy among those initially treated with intravenous corticosteroids.

77 141 with oral corticosteroids, and 143 with intravenous corticosteroids.

78 The intravenous crystalloid used in the unit alternated mont

79 h lymphodepleting conditioning chemotherapy (intravenous cyclophosphamide [60 mg/kg] daily for 2 days

80 notable and broadly consistent with previous intravenous delivery of other drugs and dyes with the hi

81 Collectively, these data validate intravenous delivery of rAAV2/9 as a novel and atraumati

82 The controlled intravenous delivery of small-molecule Wnt agonists (Dkk

83 gemcitabine 675 mg/m(2) on days 1 and 8 and intravenous docetaxel 75 mg/m(2) on day 8 every 3 weeks.

84 n interactive web response system to receive intravenous docetaxel 75 mg/m(2) plus either intravenous

85 ts (6 PC, 2 BC, and 2 UBC) received a single intravenous dose of (68)Ga-NOTA-AE105 (154 +/- 59 MBq; r

86 We infused a single intravenous dose of a codon-optimized adeno-associated v

87 mouse model of IP, we administered a single intravenous dose of the adeno-associated virus (AAV) vec

88 ndomly assigned 1:1 to receive six cycles of intravenous doxorubicin 75 mg/m(2) on day 1 every 3 week

89 Intravenous drug abuse (IVDA) is a known risk factor for

90 Intravenous drug use.

91 dministration of Nos (100 mg/kg) followed by intravenous DTX (5 mg/kg) liposome treatment revealed re

92 isorders have been an area of interest since intravenous enzyme replacement therapy was successfully

93 Whether correction of iron deficiency with (intravenous) ferric carboxymaltose (FCM) affects peak ox

94 Intravenous fluid administration up to the day of HUS di

95 The associations between hydration status, intravenous fluid administration, and outcomes of patien

96 Additional analyses incorporating intravenous fluid administration, including additional C

97 understand the effects of administration of intravenous fluid boluses and vasopressors in patients w

98 he secondary outcomes included the volume of intravenous fluid received and receipt of vasopressors.

99 target of 0.5 mL/kg/h and results in a large intravenous fluid sparing.

100 and to the completion of an initial bolus of intravenous fluid.

101 Exclusion criteria included: no intravenous fluids >/=48 hours, admission >/=14 days of

102 Clinical intravenous fluids (IVFs) of various tonicities are ofte

103 longer time to the completion of a bolus of intravenous fluids (odds ratio, 1.01 per hour; 95% CI, 0

104 3170 mL (95% confidence interval 2380-3960) intravenous fluids versus 5490 mL (95% confidence interv

105 esuscitation protocol with administration of intravenous fluids, vasopressors, and blood transfusion

106 not rapid completion of an initial bolus of intravenous fluids, were associated with lower risk-adju

107 e dose of 60 mg/m(2) on days 1 and 29), with intravenous fluorouracil (one dose of 1000 mg/m(2) per d

108 35 over 7 weeks) plus cisplatin at 100 mg/m2 intravenous for 3 doses (arm A) vs accelerated-fractiona

109 35 over 6 weeks) plus panitumumab at 9 mg/kg intravenous for 3 doses (arm B).

110 lone (USAN; formerly SAGE-547 injection), an intravenous formulation of allopregnanolone, a positive

111 We used an intravenous fractionated regimen of alpha-radioimmunothe

112 sistance (urine output </=125 ml/h following intravenous furosemide >/=40 mg).

113 Infants received intravenous furosemide (1 mg/kg every 6 hours) or a stan

114 ts with intracranial abnormalities following intravenous gadolinium-based contrast agent (GBCA) expos

115 an primate tissue after maternal exposure to intravenous gadoteridol during pregnancy.

116 ents were randomized (1:1) to receive either intravenous ganciclovir (5 mg/kg twice daily for 5 days)

117 twice daily for 5 days), followed by either intravenous ganciclovir or oral valganciclovir once dail

118 ncluded 144 pediatric patients who underwent intravenous GBCA-enhanced MR imaging examinations (55 pa

119 ubicin 75 mg/m(2) on day 1 every 3 weeks, or intravenous gemcitabine 675 mg/m(2) on days 1 and 8 and

120 Results showed that intravenous ghrelin, compared to placebo, significantly

121 A 10-min loading dose of intravenous ghrelin/placebo (3 mcg kg(-1)) followed by a

122 rom the insulin-modified, frequently sampled intravenous glucose tolerance test (FSIGT), we estimated

123 = 389) had first-phase insulin release on an intravenous glucose tolerance test that was higher than

124 Intravenous glucose tolerance tests were performed befor

125 , which occurred in 44 patients (21%) in the intravenous group and 52 (26%) in the subcutaneous group

126 nduction was 84.9% (95% CI 79.2-89.5) in the intravenous group and 84.4% (78.7-89.1) in the subcutane

127 actions occurred in 73 patients (35%) in the intravenous group and 95 (48%) patients in the subcutane

128 ent failure was significantly higher for the intravenous group than the oral group [odds ratio (OR) 1

129 ilar in both groups (199 [95%] of 210 in the intravenous group vs 189 [96%] of 197 in the subcutaneou

130 catheter line complications was 3.2% in the intravenous group, and drug reactions were rare in both

131 ding the various topical, intracavitary, and intravenous hemostatic technologies in terms of material

132 changes following repeated subcutaneous and intravenous heroin challenges in mice and rats.

133 , multicenter study evaluated the effects of intravenous high-dose NAC (29 g over 2 days) with backgr

134 C1INH attenuated pulmonary damage evoked by intravenous histone instillation.

135 de administration of oral and, as necessary, intravenous hydration; systematic monitoring of vital si

136 e randomized 1:1 to treatment with serelaxin intravenous (i.v.) infusion (for 60 min at 80 mug/kg/d a

137 cavity, enabling elevated drug levels versus intravenous (i.v.) injection.

138 open-label study to determine whether 5 g of intravenous idarucizumab would be able to reverse the an

139 Intravenous illicit drug use (IDU) and hepatitis C infec

140 to 20% of patients do not respond to initial intravenous immune globulin, and recommendations for add

141 a mouse model of EV-D68 infection: (1) human intravenous immunoglobulin (hIVIG), (2) fluoxetine, and

142 Intravenous immunoglobulin (IVIG) are purified IgG prepa

143 Intravenous immunoglobulin (IVIG) is a FDA-approved drug

144 Intravenous immunoglobulin (IVIG) is sometimes administe

145 Intravenous immunoglobulin (IVIG), a pooled normal IgG f

146 and outcome of GBS in patients treated with intravenous immunoglobulin (IVIG).

147 nduced by injection of heat-aggregated human intravenous immunoglobulin and active systemic anaphylax

148 Intravenous immunoglobulin and corticosteroids were effe

149 or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 mon

150 within 12 months before screening, or use of intravenous immunoglobulin or plasma exchange within 4 w

151 h definite or probable CIDP who responded to intravenous immunoglobulin treatment were eligible.

152 inating polyneuropathy (CIDP) need long-term intravenous immunoglobulin.

153 s among plasma donors, which is reflected in intravenous immunoglobulins (IVIGs).

154 rapy consisted of steroids (n = 61/74; 82%), intravenous immunoglobulins (n = 71/74; 96%), and plasma

155 phosphamide combined with plasmapheresis and intravenous immunoglobulins is an option for patients wi

156 d first-line immunotherapy with steroids and intravenous immunoglobulins vs. late immunotherapy), and

157 g therapies, including glucocorticosteroids, intravenous immunoglobulins, cyclosporine, plasmapheresi

158 from blood and several organs using a murine intravenous infection model.

159 e that in hamsters, pathology resulting from intravenous infection with adenoviruses is caused mostly

160 h titers in the liver of these animals after intravenous infection, while respiratory infection resul

161 s are trapped in the lungs immediately after intravenous infusion and their survival time in the host

162 Avelumab was given as a 1-h intravenous infusion every 2 weeks.

163 n every 8 h) or 1000 mg meropenem (by 30-min intravenous infusion every 8 h) for 7-14 days; regimens

164 mg ceftazidime and 500 mg avibactam (by 2 h intravenous infusion every 8 h) or 1000 mg meropenem (by

165 Patients received an intravenous infusion of 7.5 mg/kg MABp1 or placebo given

166 optimal medical treatment were randomized to intravenous infusion of allogenic UC-MSCs (Cellistem, Ce

167 lysis to compare prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams in

168 The intravenous infusion of apolipoprotein E4 exacerbated th

169 m(2)] daily for 5 days, followed by a single intravenous infusion of autologous TILs and high-dose in

170 acute heart failure to receive a continuous intravenous infusion of either ularitide at a dose of 15

171 nderwent MRI at baseline then 24 h following intravenous infusion of ketamine (0.5 mg/kg).

172 oom temperature (22 degrees C) for 4 h or by intravenous infusion of the alpha-adrenergic receptor an

173 Evaluate the safety and efficacy of the intravenous infusion of UC-MSC in patients with chronic

174 56 mg/m(2) thereafter) was given as a 30-min intravenous infusion on days 1, 2, 8, 9, 15, and 16 of 2

175 m2 intravenous, and fluorouracil, 2400 mg/m2 intravenous infusion over 46-48 hours) on days 1 and 15

176 expression received avelumab (10 mg/kg, 1 h intravenous infusion) every 2 weeks until confirmed dise

177 ), whereas direct intramyocardial injection, intravenous infusion, and intracoronary infusion indicat

178 eceived gemcitabine 1000 mg/m(2) as a 30-min intravenous infusion, weekly, for 7 weeks followed by a

179 as did direct intramyocardial injection and intravenous infusion, whereas intracoronary infusion dem

180 etermined with the use of a [1-(13)C]leucine intravenous infusion.

181 administered in 28-day cycles by continuous intravenous infusion.

182 mit physiological insight, e.g. the need for intravenous infusions and restriction to short-term stud

183 Intravenous infusions of (13)C-labelled nutrients reveal

184 andomized equally to receive 15 double-blind intravenous infusions of adjunctive lanicemine 50 mg, la

185 ntuximab, 50 mg (week 1), followed by weekly intravenous infusions of girentuximab, 20 mg (weeks 2-24

186 receive ozanezumab (15 mg/kg) or placebo as intravenous infusions over 1 h every 2 weeks for 46 week

187 onger plasma circulation than free drug upon intravenous injection in mice.

188 nd mRNA encoding Cas9, we show that a single intravenous injection into mice induces >80% editing of

189 Single-dose intravenous injection of (131)I-CLR1404 significantly de

190 Patients received a single 150-MBq intravenous injection of (68)Ga-DOTATOC (15 mug of pepti

191 /CT images were acquired 60 +/- 10 min after intravenous injection of (68)Ga-PSMA (mean dose, 176 MBq

192 e effects were observed within 90 days after intravenous injection of 250 mg kg(-1) GS-AuNPs.

193 thelialium-specific activation of miR-195 by intravenous injection of aptamer-agomiR-195 stimulates C

194 Single intravenous injection of DC nanozymes (5kU of SOD1/kg) i

195 Bacteremia was induced by intravenous injection of Escherichia coli Bacteremia cau

196 In vivo experiments revealed that intravenous injection of exosomes harvested after T/HS,

197 immunocompetent Sprague-Dawley rats received intravenous injection of ferumoxytol, and 18 Jax C57BL/6

198 the preclinical pig kidney transplant model, intravenous injection of GC7 before kidney removal signi

199 Intravenous injection of IL-33 or pulmonary fungal aller

200 Intravenous injection of Ms 9a-1 (0.3 mg/kg) produced a

201 We also show that intravenous injection of singly encapsulated marrow stro

202 However, following intravenous injection of tumor cells, mice lacking PITPa

203 retention of GC-PEG-PpIX were realized after intravenous injection, which ensured its effective imagi

204 lies on cell homing to the bone marrow after intravenous injection.

205 directly into the ossicle marrow space or by intravenous injection.

206 on scan, (11)C-nicotine was administered via intravenous injection.

207 TOC (15 mug of peptide) and 2 single 150-MBq intravenous injections of (68)Ga-OPS202 (15 mug of pepti

208 Patients received 2 single 150-MBq intravenous injections of (68)Ga-OPS202 3-4 wk apart (15

209 tee-approved study, healthy rats received 20 intravenous injections of 2.5 mmol gadolinium per kilogr

210 the last 3 weeks, a subset of rats received intravenous injections of lipopolysaccharide (LPS, 3 mg/

211 ce with oral ginsenoside Ro followed by HT29 intravenous inoculation and 40-day oral ginsenoside Ro s

212 nasal insulin application was mimicked by an intravenous insulin bolus on placebo day.

213 s similar in AAs and EAs after the 20-25 min intravenous insulin infusion.

214 ping renal toxicity due to administration of intravenous iodine- and gadolinium-based contrast materi

215 eived intravenous pembrolizumab 2 mg/kg plus intravenous ipilimumab 1 mg/kg every 3 weeks for four do

216 nous pembrolizumab every 3 weeks (n=277), or intravenous ipilimumab every 3 weeks (ipilimumab for fou

217 ); higher transferrin iron saturation index; intravenous iron use for anemia (adjusted odds ratio, 5.

218 Compared to free doxorubicin, a single intravenous (IV) administration of CP-Dox at the maximum

219 re determined following single oral (PO) and intravenous (IV) administration to cockatiels (Nymphicus

220 r cellular potency to be compatible with the intravenous (iv) dosing route required in AP.

221 el treatments, we have generated an improved intravenous (IV) formulation of HET0016 with HPssCD and

222 C01 administered either subcutaneously or by intravenous (IV) infusion and to assess the pharmacokine

223 safety and efficacy of 2 different doses of intravenous (IV) infusions of tocilizumab (TCZ), an IL-6

224 of the peptide into the CSF compared to the intravenous (IV) route, which requires blood-brain barri

225 h DSM-5 SAD and compared the effects between intravenous ketamine (0.5 mg/kg over 40 min) and placebo

226 the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal

227 In patients with bouts of OHE, intravenous LOLA (as an add-on therapy to lactulose and

228 We evaluated the efficacy of intravenous LOLA in the reversal of bouts of OHE in pati

229 aintains prolonged voluntary abstinence from intravenous methamphetamine self-administration, to demo

230 n 54 of these participants, we also measured intravenous methylphenidate-induced dopamine release to

231 erate-to-severe ARDS onset to receive either intravenous midazolam or inhaled sevoflurane for 48 hour

232 patients (by minimisation) to receive either intravenous mitomycin (one dose of 12 mg/m(2) on day 1)

233 lgorithms and pointed to circumstances where intravenous monotherapy may be inadequate.

234 Intravenous MSCs eliminated the progressive deterioratio

235 placebo-controlled, dose-escalation trial of intravenous multipotent adult progenitor cells in 33 cen

236 D18 integrin-deficient (CD11b(-/-)) mice and intravenous myeloperoxidase infusion revealed that neutr

237 High-dose intravenous NAC administered with low-dose intravenous n

238 We demonstrated that intravenous NAC administration promotes lysis of arteria

239 ent sample of smokers who participated in an intravenous nicotine infusion study that followed overni

240 e intravenous NAC administered with low-dose intravenous nitroglycerin is associated with reduced inf

241 ents and Methods Patients with mRCC received intravenous nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (N

242 carmustine plus 2 subsequent daily doses of intravenous O6-benzylguanine, administered every 2 weeks

243 multiple sclerosis in a 2:1 ratio to receive intravenous ocrelizumab (600 mg) or placebo every 24 wee

244 with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 wee

245 o assess the safety and clinical activity of intravenous ofatumumab monotherapy for untreated and rel

246 to evaluate the efficacy of the parenteral (intravenous or intramuscular) ondansetron vs traditional

247 Human immunoglobulin preparations for intravenous or subcutaneous administration are the corne

248 In mice, intravenous or sublingual administration of ICM led to a

249 GEN-5416/hypoxia-induced PAH rats than oral, intravenous, or intratracheal plain sildenafil did, when

250 arlisib (100 mg once daily) or placebo, plus intravenous paclitaxel (80 mg/m(2) on days 1, 8, 15, and

251 compare thoracic epidural analgesia (TEA) to intravenous patient-controlled analgesia (IV-PCA) for pa

252 patients were randomized to TEA (N = 106) or intravenous patient-controlled analgesia (N = 34).

253 kg every 3 weeks for four doses, followed by intravenous pembrolizumab 2 mg/kg every 3 weeks for up t

254 Patients received intravenous pembrolizumab 2 mg/kg plus intravenous ipili

255 re enrolled and randomly assigned to receive intravenous pembrolizumab every 2 weeks (n=279), intrave

256 avenous pembrolizumab every 2 weeks (n=279), intravenous pembrolizumab every 3 weeks (n=277), or intr

257 All patients were treated with 200 mg intravenous pembrolizumab every 3 weeks.

258 and the absence of intraoperative lidocaine intravenous perfusion (odds ratio: 0.182, 95% CI 0.042-0

259 Intravenous Pi loading (0.5 mmol) caused a transient ris

260 Conclusion Accelerated intravenous premedication with corticosteroids beginning

261 egnancy BMI >/=30) who had received standard intravenous preoperative cephalosporin prophylaxis.

262 Intravenous preparations have a number of important uses

263 ts The breakthrough reaction rate for 5-hour intravenous prophylaxis was 2.5% (five of 202 patients;

264 intravenous docetaxel 75 mg/m(2) plus either intravenous ramucirumab 10 mg/kg or matching placebo on

265 the case management of cholera with oral and intravenous rehydration therapy have reduced the case fa

266 ks, followed by combined therapy with 250 mg intravenous REP 2139 and 180 mug subcutaneous pegylated

267 Patients received 500 mg intravenous REP 2139 once per week for 15 weeks, followe

268 non-inferiority of subcutaneous rituximab to intravenous rituximab in follicular lymphoma and to prov

269 Intravenous rituximab is the standard of care in B-cell

270 to 6-month therapy with NIAT and 375 mg/m(2) intravenous rituximab on days 1 and 8 (n=37) or NIAT alo

271 g capacity through either the enteral or the intravenous route is approximately 160 mumol/hour in con

272 als challenged with SHIVAD8-EO by mucosal or intravenous routes received a single 2-week course of tw

273 Intravenous rt-PA (recombinant tissue-type plasminogen a

274 s should evaluate the safety and efficacy of intravenous rt-PA in patients with ischemic stroke who a

275 7 patients with ischemic stroke treated with intravenous rt-PA within 4.5 hours, 251 were taking NOAC

276 he diagnosis was confirmed or excluded by an intravenous saline infusion test or captopril challenge

277 d responding for and intake of cocaine in an intravenous self-administration test.

278 actice of treating PAH patients with oral or intravenous sildenafil suffers from the limitations of s

279 Intravenous, single-dose administration of fibrinogen co

280 Intravenous sodium bicarbonate and oral acetylcysteine a

281 Intravenous thrombolysis (IVT) followed by mechanical th

282 However, it is not known whether intravenous thrombolysis (IVT) is of added benefit in pa

283 y performance indicator for efficient use of intravenous thrombolysis in acute ischemic stroke (AIS).

284 Intravenous thrombolysis with tissue-type plasminogen ac

285 Six patients (4%) received intravenous tissue plasminogen activator without complic

286 for all transferred patients suggested that intravenous tissue plasminogen activator would be delaye

287 ae, and the possibility to offer patients an intravenous-to-oral switch therapy was supported by the

288 te ischaemic stroke patients with or without intravenous tPA treatment, compared to 115 age and gende

289 1 ischemic stroke patients were treated with intravenous tPA within 4.5 hours of symptom onset from 8

290 However, there is an unmet need for intravenous treatment for patients admitted to hospital

291 Intravenous treatment of mice with adenosine or agonists

292 interactive voice or web system, to receive intravenous tremelimumab (10 mg/kg) or placebo every 4 w

293 Intravenous urography, voiding cysto-urethrography and M

294 Ultrasound examination was followed by intravenous urography, voiding cysto-urethrography and M

295 te heart failure, early intervention with an intravenous vasodilator has been proposed as a therapeut

296 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with sta

297 nts were randomly assigned to receive 300 mg intravenous zanamivir (n=201), 600 mg intravenous zanami

298 300 mg intravenous zanamivir (n=201), 600 mg intravenous zanamivir (n=209), or 75 mg oral oseltamivir

299 95% CI -1.79 to 0.75; p=0.25) in the 300 mg intravenous zanamivir group and 5.63 days (difference of

300 clinical response of 5.14 days in the 600 mg intravenous zanamivir group, the median time to clinical

301 ays or 5-6 days) to receive 300 mg or 600 mg intravenous zanamivir, or standard-of-care (75 mg oral o